Literature DB >> 6539201

Patient motivation and informed consent in a phase I study of an anticancer agent.

S Rodenhuis, W J van den Heuvel, A A Annyas, H S Koops, D T Sleijfer, N H Mulder.   

Abstract

In order to evaluate the quality of an informed consent procedure (I.C.P.) 48 patients with advanced cancer were offered participation in a phase I clinical trial and entered an I.C.P. consisting of three separate conversations. In the first session, the possible risks and benefits of a phase I study were informally explained by the patient's personal physician. The second session was attended by the patient, a relative, a registered nurse and a physician; the third session was held at least 5 days after the second. Forty-one patients gave their consent motivated by hope for improvement of their conditions, pressure exerted by relatives and friends, the desire to contribute to the progress of medicine or simply because they felt they had 'no choice'. Encouragement by relatives or friends seems to be a powerful incentive to participate. A period of a few days to consult relatives, friends or trusted physicians as a part of the procedure seems helpful in arriving at a well-considered decision.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Substances:

Year:  1984        PMID: 6539201     DOI: 10.1016/0277-5379(84)90229-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  22 in total

Review 1.  Ethical issues in the development of new agents.

Authors:  C K Daugherty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  [Motivation of patients to participate in clinical trials. An explorative survey].

Authors:  Charly Gaul; Annett Malcherczyk; Thomas Schmidt; Jürgen Helm; Johannes Haerting
Journal:  Med Klin (Munich)       Date:  2010-02-20

Review 3.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

Review 4.  The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals.

Authors:  S J Edwards; R J Lilford; J Hewison
Journal:  BMJ       Date:  1998-10-31

5.  The use of multimedia in the informed consent process.

Authors:  H B Jimison; P P Sher; R Appleyard; Y LeVernois
Journal:  J Am Med Inform Assoc       Date:  1998 May-Jun       Impact factor: 4.497

6.  Informing patients about clinical trials.

Authors:  B J Oddens; A Algra; J van Gijn
Journal:  Clin Investig       Date:  1993-07

7.  Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.

Authors:  Katherine E Reeder-Hayes; Megan C Roberts; Gail E Henderson; Elizabeth C Dees
Journal:  J Oncol Pract       Date:  2017-08-24       Impact factor: 3.840

8.  Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.

Authors:  Rebecca D Pentz; Margaret White; R Donald Harvey; Zachary Luke Farmer; Yuan Liu; Colleen Lewis; Olga Dashevskaya; Taofeek Owonikoko; Fadlo R Khuri
Journal:  Cancer       Date:  2012-01-31       Impact factor: 6.860

9.  Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Authors:  Fay J Hlubocky; Greg A Sachs; Eric R Larson; Halla S Nimeiri; David Cella; Kristen E Wroblewski; Mark J Ratain; Jeffery M Peppercorn; Christopher K Daugherty
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

10.  Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear?

Authors:  Nancy Kass; Holly Taylor; Linda Fogarty; Jeremy Sugarman; Steven N Goodman; Annallys Goodwin-Landher; Michael Carducci; Herbert Hurwitz
Journal:  J Empir Res Hum Res Ethics       Date:  2008-09       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.